Asako Yoshizaki‐Ogawa

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

Satoshi Ebata, Ayumi Yoshizaki, Koji Oba et al. · The Lancet Rheumatology · 2021 · 259 citations

Medicine, Immunology, Pharmacotherapy +8

Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis

Ai Kuzumi, Ayumi Yoshizaki, Kazuki Matsuda et al. · Nature Communications · 2021 · 81 citations · Full text

Medicine, Immunology, Pathology +17

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

Satoshi Ebata, Ayumi Yoshizaki, Koji Oba et al. · The Lancet Rheumatology · 2022 · 75 citations

Medicine, Immunology, Pharmacotherapy +10

Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis

Kazuki Matsuda, Ayumi Yoshizaki, Ai Kuzumi et al. · The Journal of Dermatology · 2020 · 55 citations

Life Sciences, Dermatology, Immunology +17

B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis

Hiroko Numajiri, Ai Kuzumi, Takemichi Fukasawa et al. · Arthritis & Rheumatology · 2021 · 49 citations

Life Sciences, Immunology, Pathology +17